183 related articles for article (PubMed ID: 37636077)
21. Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.
Su Z; Zheng X; Zhang X; Wang Y; Zhu S; Lu F; Qu J; Hou L
J Dermatol Sci; 2017 Mar; 85(3):216-225. PubMed ID: 27955842
[TBL] [Abstract][Full Text] [Related]
22. Tumor-Infiltrating PD-1
Yang Z; Deng Y; Cheng J; Wei S; Luo H; Liu L
Front Oncol; 2021; 11():695006. PubMed ID: 34604032
[TBL] [Abstract][Full Text] [Related]
23. Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma.
Yu J; Wu X; Song J; Zhao Y; Li H; Luo M; Liu X
Front Pharmacol; 2022; 13():928226. PubMed ID: 36091815
[TBL] [Abstract][Full Text] [Related]
24. SOX10-regulated promoter use defines isoform-specific gene expression in Schwann cells.
Fogarty EA; Kitzman JO; Antonellis A
BMC Genomics; 2020 Aug; 21(1):549. PubMed ID: 32770939
[TBL] [Abstract][Full Text] [Related]
25. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.
Han S; Ren Y; He W; Liu H; Zhi Z; Zhu X; Yang T; Rong Y; Ma B; Purwin TJ; Ouyang Z; Li C; Wang X; Wang X; Yang H; Zheng Y; Aplin AE; Liu J; Shao Y
Nat Commun; 2018 Jan; 9(1):28. PubMed ID: 29295999
[TBL] [Abstract][Full Text] [Related]
26. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Shoushtari AN; Chatila WK; Arora A; Sanchez-Vega F; Kantheti HS; Rojas Zamalloa JA; Krieger P; Callahan MK; Betof Warner A; Postow MA; Momtaz P; Nair S; Ariyan CE; Barker CA; Brady MS; Coit DG; Rosen N; Chapman PB; Busam KJ; Solit DB; Panageas KS; Wolchok JD; Schultz N
Clin Cancer Res; 2021 Apr; 27(8):2226-2235. PubMed ID: 33509808
[TBL] [Abstract][Full Text] [Related]
28. Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.
Nguyen TT; Ramsay L; Ahanfeshar-Adams M; Lajoie M; Schadendorf D; Alain T; Watson IR
Clin Cancer Res; 2021 Jun; 27(12):3432-3442. PubMed ID: 33593882
[TBL] [Abstract][Full Text] [Related]
29. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas.
Ivanov SV; Panaccione A; Nonaka D; Prasad ML; Boyd KL; Brown B; Guo Y; Sewell A; Yarbrough WG
Br J Cancer; 2013 Jul; 109(2):444-51. PubMed ID: 23799842
[TBL] [Abstract][Full Text] [Related]
31. SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis.
Cronin JC; Watkins-Chow DE; Incao A; Hasskamp JH; Schönewolf N; Aoude LG; Hayward NK; Bastian BC; Dummer R; Loftus SK; Pavan WJ
Cancer Res; 2013 Sep; 73(18):5709-18. PubMed ID: 23913827
[TBL] [Abstract][Full Text] [Related]
32. Functional in vivo characterization of sox10 enhancers in neural crest and melanoma development.
Cunningham RL; Kramer ET; DeGeorgia SK; Godoy PM; Zarov AP; Seneviratne S; Grigura V; Kaufman CK
Commun Biol; 2021 Jun; 4(1):695. PubMed ID: 34099848
[TBL] [Abstract][Full Text] [Related]
33. SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity.
Graf SA; Busch C; Bosserhoff AK; Besch R; Berking C
J Invest Dermatol; 2014 Aug; 134(8):2212-2220. PubMed ID: 24608986
[TBL] [Abstract][Full Text] [Related]
34. Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers.
Panaccione A; Guo Y; Yarbrough WG; Ivanov SV
Clin Breast Cancer; 2017 Jul; 17(4):298-306.e7. PubMed ID: 28216417
[TBL] [Abstract][Full Text] [Related]
35. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
Wrede N; Hoffmann I; Vollbrecht C; Koch I; Wolkenstein P; Klauschen F; Capper D; von Laffert M; Jurmeister P
Pathol Res Pract; 2022 Jan; 229():153689. PubMed ID: 34844086
[TBL] [Abstract][Full Text] [Related]
36. SOX10-MITF pathway activity in melanoma cells.
Tudrej KB; Czepielewska E; Kozłowska-Wojciechowska M
Arch Med Sci; 2017 Oct; 13(6):1493-1503. PubMed ID: 29181082
[TBL] [Abstract][Full Text] [Related]
37. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment.
Szumera-Ciećkiewicz A; Bosisio F; Teterycz P; Antoranz A; Delogu F; Koljenović S; van de Wiel BA; Blokx W; van Kempen LC; Rutkowski P; Christopher van Akkooi A; Cook M; Massi D;
Eur J Cancer; 2020 Sep; 137():175-182. PubMed ID: 32781392
[TBL] [Abstract][Full Text] [Related]
38. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
39. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.
Motti ML; Minopoli M; Di Carluccio G; Ascierto PA; Carriero MV
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
